Informe completo: Autologous haematopoietic stem cell transplantation for previously treated, relapsing-remitting multiple sclerosis
Resumen: Autologous haematopoietic stem cell transplantation
Objetivo: Health Technology Wales undertook an evidence review to address the following question: is autologous haematopoietic stem cell transplantation (AHSCT) clinically and cost-effective for previously treated, relapsing-remitting multiple sclerosis (RRMS)?
Autoría: Health Technology Wales
Idioma: inglés
Fuente: INAHTA
Año de publicación: 2020